Stryker (SYK) Stock

$395.20 -3.89 (-0.97%)
Market Cap: $150.66B | NYSE

Stryker Chart


Company Profile

Price: $395.20

Market Cap: $150.66B

Exchange: NYSE

CEO: Mr. Kevin A. Lobo

Sector: Healthcare

Industry: Medical - Devices

Employees: 52.00K

Headquarters: Kalamazoo, MI

Website: Stryker

Business Summary

Stryker Corporation operates as a medical technology company. The company operates through two segments, MedSurg and Neurotechnology, and Orthopaedics and Spine. The Orthopaedics and Spine segment provides implants for use in hip and knee joint replacements, and trauma and extremities surgeries. This segment also offers spinal implant products comprising cervical, thoracolumbar, and interbody systems that are used in spinal injury, deformity, and degenerative therapies. The MedSurg and Neurotechnology segment offers surgical equipment and surgical navigation systems, endoscopic and communications systems, patient handling, emergency medical equipment and intensive care disposable products, reprocessed and remanufactured medical devices, and other medical device products that are used in various medical specialties. This segment also provides neurotechnology products, which include products used for minimally invasive endovascular techniques; products for brain and open skull based surgical procedures; orthobiologic and biosurgery products, such as synthetic bone grafts and vertebral augmentation products; minimally invasive products for the treatment of acute ischemic and hemorrhagic stroke; and craniomaxillofacial implant products, including cranial, maxillofacial, and chest wall devices, as well as dural substitutes and sealants. The company sells its products to doctors, hospitals, and other healthcare facilities through company-owned subsidiaries and branches, as well as third-party dealers and distributors in approximately 75 countries. Stryker Corporation was founded in 1941 and is headquartered in Kalamazoo, Michigan.

Stryker News

Sales Growth, Strategic Acquisitions Drive Stryker Higher

Medical device maker Stryker Corporation (SYK) benefits from more procedures, sales, and acquisitions.

News image

Will Cheaper AI Models Like DeepSeek Become a Boon? 3 Stocks to Watch

As costs related to AI models may come down, as is evident from the cheaper DeepSeek model from China, MedTech companies developing AI-based solutions like SYK, BSX and TEM are likely to gain.

News image

Stryker's Strategic Moves Impress Analysts, Spine Implant Sale and NARI Deal Set to Drive Future Growth

Wall Street analysts rerated Stryker Corp SYK Wednesday after the company's fourth-quarter print.

News image

Stryker Stock Falls on Deal to Sell Its U.S. Spinal Implants Business

SYK announces agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC.

News image

SYK Stock Down Despite Q4 Earnings Beat and Spine Biz Divestment Plans

SYK's fourth-quarter results reflect strong segmental performance, along with a rise in operating margin.

News image

Stryker Corporation (SYK) Q4 2024 Earnings Conference Call Transcript

Stryker Corporation (NYSE:SYK ) Q4 2024 Earnings Conference Call January 28, 2025 4:30 PM ET Company Participants Kevin Lobo - Chairman, CEO & President Andy Pierce - Group President of MedSurg & Neurotechnology Jason Beach - Vice President, Finance and Investor Relations Glenn Boehnlein - Vice President, Chief Financial Officer Conference Call Participants Lawrence Biegelsen - Wells Fargo Securities Robert Marcus - JPMorgan Travis Steed - Bank of America David Roman - Goldman Sachs Pito Chickering - Deutsche Bank Vijay Kumar - Evercore ISI Matthew O'Brien - Piper Sandler Companies Shagun Singh - RBC Matthew Miksic - Barclays Michael Matson - Needham & Company Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Josh Jennings - TD Cowen Danielle Antalffy - UBS Equities Michael Polark - Wolfe Research Operator Welcome to the Fourth Quarter 2024 Stryker Earnings Call. My name is Luke, and I'll be your operator for today's call.

News image

Stryker (SYK) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for Stryker (SYK) give a sense of how its business performed in the quarter ended December 2024, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

News image

Stryker (SYK) Q4 Earnings and Revenues Surpass Estimates

Stryker (SYK) came out with quarterly earnings of $4.01 per share, beating the Zacks Consensus Estimate of $3.87 per share. This compares to earnings of $3.46 per share a year ago.

News image

Stryker forecasts 2025 profit above estimates on robust demand for surgical devices

Stryker beat Wall Street estimates for fourth-quarter profit and forecast 2025 earnings largely above expectations on Tuesday, fueled by strong demand for its medical and surgical devices.

News image

Overlooked Stock: SYK

Stryker Corp. (SYK) ticked higher after hours after the medical tech company posted an earnings beat. George Tsilis turned to how a rally from this mostly unseen stock reflects the healthcare industry.

News image

Stryker announces definitive agreement for the sale of its U.S. spinal implants business and plans to sell related international business

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK), a global leader in medical technologies, announced today a definitive agreement to sell its U.S. spinal implants business to Viscogliosi Brothers, LLC, a family-owned investment firm specializing in the neuro-musculoskeletal space, to create a newly formed company called VB Spine, LLC.

News image

Stryker announces the retirement of Glenn S. Boehnlein and the promotion of Preston Wells to Vice President, Chief Financial Officer

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) announced today that Glenn S. Boehnlein will retire from his role as Vice President, Chief Financial Officer. Boehnlein's decision follows an impressive 22-year career at Stryker. Preston Wells, who currently serves as Group CFO for Stryker's Orthopaedics Group, will assume the role of Vice President, Chief Financial Officer effective April 1, 2025.

News image

Stryker reports 2024 operating results and 2025 outlook

Portage, Michigan, Jan. 28, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE:SYK) reported operating results for the fourth quarter and full year of 2024:

News image

Strong Segmental Performance to Drive Stryker's Q4 Earnings?

SYK's fourth-quarter 2024 results are expected to reflect strong segmental performance. However, rising costs are likely to have continued to hurt margins.

News image

Stryker: A Cool Name For An Awesome Company, But Is It A Buy Ahead Of Earnings?

Stryker Corporation is a high-quality, innovative medical device company with a strong history of revenue, earnings, and FCF growth, driven by R&D and M&A strategies. Shares are currently expensive with a PEG ratio around 3, but the company's consistent performance and market leadership justify a premium valuation. Stryker's strong company culture, impressive ROIC, and substantial insider ownership indicate a durable competitive advantage and a bright future.

News image

PAHC vs. SYK: Which Stock Should Value Investors Buy Now?

Investors interested in stocks from the Medical - Products sector have probably already heard of Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

News image

Stryker (SYK) Q4 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

Beyond analysts' top -and-bottom-line estimates for Stryker (SYK), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended December 2024.

News image

Stryker commences tender offer for all outstanding shares of common stock of Inari Medical, Inc.

Portage, Michigan, Jan. 17, 2025 (GLOBE NEWSWIRE) -- Stryker (NYSE: SYK) today announced that it is commencing, through a wholly owned subsidiary, Eagle 1 Merger Sub, Inc., a cash tender offer to purchase all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80.00 per share in cash. The offer is being made pursuant to the previously announced merger agreement, dated as of January 6, 2025, among Stryker, Eagle 1 Merger Sub, Inc and Inari.

News image

PAHC or SYK: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Products stocks are likely familiar with Phibro Animal Health (PAHC) and Stryker (SYK). But which of these two stocks presents investors with the better value opportunity right now?

News image

INARI MEDICAL INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Inari Medical, Inc. - NARI

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Inari Medical, Inc. (NasdaqGS: NARI) to Stryker (NYSE: SYK). Under the terms of the proposed transaction, shareholders of Inari will receive $80.00 in cash for each share of Inari that they own. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the c.

News image

Stryker Stock Falls Despite the Agreement to Acquire Inari Medical

SYK inks an agreement to acquire Inari Medical at a valuation of approximately $4.9 billion.

News image

Inari Shares Skyrocket As Stryker Will Acquire Medical Device Maker for $4.9B

Inari Medical (NARI) stock skyrocketed Monday afternoon and again Tuesday morning after a report that it was close to being acquired by Stryker (SYK) proved to be true.

News image

Stryker To Buy Inari Medical In $5 Billion Deal To Bolster Venous Thromboembolism Position

On Monday, Stryker Corporation SYK agreed to acquire Inari Medical Inc. NARI for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion.

News image

Inari Medical Catapults — Again — After Stryker Confirms $4.9 Billion Deal

Medical devices behemoth Stryker agreed to buy Inari Medical for $4.9 billion late Monday. Inari stock catapulted on the news.

News image

Stryker announces definitive agreement to acquire Inari Medical, Inc., providing entry into high-growth peripheral vascular segment

Portage, Michigan and Irvine, California, Jan. 06, 2025 (GLOBE NEWSWIRE) --  Stryker (NYSE: SYK), a global leader in medical technologies, announced today a definitive agreement to acquire all of the issued and outstanding shares of common stock of Inari Medical, Inc. (NASDAQ: NARI) for $80 per share in cash, representing a total fully diluted equity value of approximately $4.9 billion. Inari, which was founded in 2011, will bring a leading peripheral vascular position in the fast-growing segment of venous thromboembolism (VTE) to Stryker. Inari's innovative product portfolio is highly complementary to Stryker's Neurovascular business and includes mechanical thrombectomy solutions for peripheral vascular diseases such as deep vein thrombosis and pulmonary embolism.

News image

Exclusive: Medical device maker Stryker nearing a deal to buy Inari Medical, sources say

Medical-device maker Stryker is in advanced talks to acquire Inari Medical , which makes devices that treat patients with venous diseases, people familiar with the matter told Reuters on Monday.

News image

3 Stocks Helping Bring AI to Healthcare

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis.

News image

5 MedTech Stocks That Are Poised to Beat the Market in 2025

Here, we discuss five stocks that are likely to generate better than the market, driven by strong demand for existing products and the addition of innovative new devices.

News image

HAE or SYK: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Products stocks have likely encountered both Haemonetics (HAE) and Stryker (SYK). But which of these two companies is the best option for those looking for undervalued stocks?

News image

Stryker Earnings

This section highlights Stryker's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.

Next Earnings Date

Date: April 29, 2025
Time: After Market
Est. EPS: $2.77
Status: Unconfirmed

Last Earnings Results

Date: January 28, 2025
EPS: $4.01
Est. EPS: $3.87
Revenue: $6.44B

Earnings Call Transcripts

Transcript Quarter Year Date Estimated EPS Actual EPS
Read Transcript Q4 2024 2025-01-28 $3.87 $4.01
Read Transcript Q3 2024 2024-10-29 $2.77 $2.87
Read Transcript Q2 2024 2024-07-30 $2.79 $2.81
Read Transcript Q1 2024 2024-04-30 $2.35 $2.50
Read Transcript Q4 2023 2024-01-30 $3.27 $3.46
Read Transcript Q3 2023 2023-11-02 $2.44 $2.46
Read Transcript Q2 2023 2023-08-03 $2.38 $2.54
Read Transcript Q1 2023 2023-05-01 $2.00 $2.14

Financial Statements

Access annual & quarterly financial statements for Stryker, including income statements, balance sheets, and cash flow statements..

Annual Income Statement

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Revenue $20.50B $18.45B $17.11B $14.35B $14.88B
Cost of Revenue $7.40B $6.87B $6.14B $5.29B $5.19B
Gross Profit $13.10B $11.58B $10.97B $9.06B $9.70B
Gross Profit Ratio 63.89% 62.76% 64.11% 63.11% 65.14%
Research and Development Expenses $1.39B $1.45B $1.24B $984.00M $971.00M
General and Administrative Expenses $- $- $- $- $-
Selling and Marketing Expenses $- $- $- $- $-
Selling General and Administrative Expenses $6.92B $6.46B $6.43B $5.36B $5.36B
Other Expenses $901.00M $627.00M $619.00M $472.00M $464.00M
Operating Expenses $9.21B $8.54B $8.28B $6.82B $6.79B
Cost and Expenses $16.61B $15.41B $14.42B $12.11B $11.98B
Interest Income $75.00M $94.00M $68.00M $102.00M $155.00M
Interest Expense $356.00M $158.00M $337.00M $315.00M $287.00M
Depreciation and Amortization $1.03B $998.00M $990.00M $812.00M $778.00M
EBITDA $4.93B $4.54B $4.65B $3.75B $4.18B
EBITDA Ratio 24.07% 22.99% 22.09% 21.39% 26.03%
Operating Income $3.89B $2.84B $2.58B $2.22B $2.71B
Operating Income Ratio 18.97% 15.40% 15.10% 15.49% 18.23%
Total Other Income Expenses Net $-215.00M $-158.00M $-303.00M $-269.00M $-151.00M
Income Before Tax $3.67B $2.68B $2.28B $1.95B $2.56B
Income Before Tax Ratio 17.92% 14.54% 13.33% 13.62% 17.21%
Income Tax Expense $508.00M $325.00M $287.00M $355.00M $479.00M
Net Income $3.17B $2.36B $1.99B $1.60B $2.08B
Net Income Ratio 15.44% 12.78% 11.66% 11.14% 13.99%
EPS $8.34 $6.23 $5.29 $4.26 $5.57
EPS Diluted $8.25 $6.17 $5.22 $4.20 $5.48
Weighted Average Shares Outstanding 379.60M 378.20M 377.00M 375.50M 374.00M
Weighted Average Shares Outstanding Diluted 383.70M 382.20M 382.30M 380.30M 379.90M
SEC Filing Source Source Source Source Source


Income Statement Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Revenue $6.44B $5.49B $5.42B $5.24B $5.82B $4.91B $5.00B $4.78B $5.20B $4.48B $4.49B $4.28B $4.70B $4.16B $4.29B $3.95B $4.26B $3.74B $2.76B $3.59B
Cost of Revenue $2.26B $1.98B $2.10B $2.06B $2.11B $1.75B $1.81B $1.76B $1.97B $1.70B $1.67B $1.54B $1.66B $1.52B $1.52B $1.44B $1.54B $1.28B $1.22B $1.26B
Gross Profit $4.17B $3.52B $3.32B $3.18B $3.70B $3.16B $3.18B $3.02B $3.24B $2.78B $2.83B $2.73B $3.04B $2.64B $2.77B $2.51B $2.72B $2.46B $1.55B $2.33B
Gross Profit Ratio 64.85% 64.02% 61.31% 60.73% 63.68% 64.33% 63.67% 63.12% 62.21% 62.11% 62.90% 63.95% 64.77% 63.51% 64.56% 63.47% 63.75% 65.85% 56.01% 64.97%
Research and Development Expenses $358.00M $377.00M $352.00M $368.00M $350.00M $353.00M $346.00M $339.00M $326.00M $364.00M $351.00M $413.00M $331.00M $306.00M $310.00M $288.00M $255.00M $242.00M $233.00M $254.00M
General and Administrative Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $1.23B $1.33B
Selling and Marketing Expenses $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Selling General and Administrative Expenses $2.12B $1.90B $1.81B $1.84B $1.94B $1.70B $1.71B $1.78B $1.75B $1.46B $1.54B $1.71B $1.75B $1.60B $1.50B $1.57B $1.56B $1.24B $1.23B $1.33B
Other Expenses $- $159.00M $-53.00M $-49.00M $-31.00M $-62.00M $-66.00M $161.00M $158.00M $159.00M $160.00M $150.00M $-62.00M $-79.00M $-70.00M $-92.00M $-78.00M $-79.00M $-67.00M $-45.00M
Operating Expenses $2.48B $2.43B $2.17B $2.21B $2.44B $2.22B $2.21B $2.28B $2.23B $1.98B $2.05B $2.27B $2.22B $2.05B $1.96B $2.04B $1.95B $1.60B $1.57B $1.70B
Cost and Expenses $4.74B $4.41B $4.26B $4.27B $4.55B $3.97B $4.03B $4.04B $4.20B $3.67B $3.72B $3.81B $3.88B $3.57B $3.49B $3.49B $3.49B $2.88B $2.78B $2.96B
Interest Income $- $- $- $- $35.00M $15.00M $11.00M $14.00M $33.00M $26.00M $- $- $- $- $- $- $- $- $- $-
Interest Expense $- $- $- $- $- $- $- $56.00M $53.00M $- $52.00M $61.00M $- $- $- $- $- $- $- $-
Depreciation and Amortization $- $268.00M $258.00M $260.00M $250.00M $262.00M $259.00M $257.00M $253.00M $250.00M $253.00M $242.00M $238.00M $235.00M $241.00M $276.00M $223.00M $198.00M $193.00M $198.00M
EBITDA $581.00M $1.35B $1.31B $1.23B $1.59B $1.19B $1.22B $992.00M $1.42B $1.03B $1.13B $927.00M $1.34B $1.12B $1.18B $999.00M $1.33B $1.11B $173.00M $914.00M
EBITDA Ratio 9.03% 24.63% 26.12% 23.57% 26.12% 24.67% 24.62% 20.76% 27.70% 23.44% 22.99% 16.77% 22.70% 20.22% 26.20% 18.90% 23.79% 28.39% 6.26% 22.88%
Operating Income $581.00M $1.08B $1.16B $976.00M $1.26B $931.00M $965.00M $735.00M $1.19B $808.00M $772.00M $447.00M $819.00M $574.00M $732.00M $459.00M $749.00M $859.00M $-20.00M $635.00M
Operating Income Ratio 9.03% 19.75% 21.36% 18.62% 21.62% 18.97% 19.32% 15.38% 22.84% 18.04% 17.18% 10.46% 17.42% 13.80% 17.05% 11.61% 17.57% 22.99% -0.72% 17.70%
Total Other Income Expenses Net $-53.00M $-42.00M $-53.00M $-49.00M $-31.00M $-62.00M $-66.00M $-56.00M $-53.00M $8.00M $-52.00M $-61.00M $-62.00M $-79.00M $-70.00M $-92.00M $-78.00M $-79.00M $-67.00M $-45.00M
Income Before Tax $528.00M $1.04B $998.00M $923.00M $1.23B $869.00M $899.00M $679.00M $761.00M $816.00M $720.00M $386.00M $757.00M $495.00M $662.00M $367.00M $671.00M $780.00M $-87.00M $590.00M
Income Before Tax Ratio 8.20% 18.98% 18.41% 17.60% 21.08% 17.70% 17.99% 14.21% 14.63% 18.22% 16.02% 9.03% 16.10% 11.90% 15.42% 9.28% 15.74% 20.87% -3.15% 16.44%
Income Tax Expense $-18.00M $209.00M $173.00M $135.00M $83.00M $177.00M $161.00M $87.00M $198.00M $-8.00M $64.00M $63.00M $95.00M $57.00M $70.00M $65.00M $103.00M $159.00M $-4.00M $97.00M
Net Income $546.00M $834.00M $825.00M $788.00M $1.14B $692.00M $738.00M $592.00M $563.00M $816.00M $656.00M $323.00M $662.00M $438.00M $592.00M $302.00M $568.00M $621.00M $-83.00M $493.00M
Net Income Ratio 8.48% 15.18% 15.22% 15.03% 19.66% 14.10% 14.77% 12.39% 10.82% 18.22% 14.60% 7.56% 14.08% 10.53% 13.79% 7.64% 13.33% 16.62% -3.00% 13.74%
EPS $1.43 $2.19 $2.17 $2.07 $3.01 $1.82 $1.94 $1.56 $1.49 $2.16 $1.73 $0.86 $1.75 $1.17 $1.57 $0.80 $1.51 $1.66 $-0.22 $1.32
EPS Diluted $1.41 $2.16 $2.14 $2.05 $2.98 $1.80 $1.92 $1.54 $1.47 $2.14 $1.72 $0.84 $1.73 $1.14 $1.55 $0.79 $1.49 $1.63 $-0.22 $1.30
Weighted Average Shares Outstanding 381.30M 381.10M 381.00M 380.40M 380.00M 379.80M 379.70M 379.00M 378.50M 378.40M 378.30M 377.70M 377.30M 377.10M 376.90M 376.30M 375.90M 375.70M 375.50M 374.80M
Weighted Average Shares Outstanding Diluted 386.10M 385.60M 385.40M 385.10M 383.90M 384.00M 383.90M 383.20M 382.30M 381.80M 382.20M 382.70M 382.70M 382.70M 382.30M 381.70M 381.30M 380.20M 375.50M 379.70M
SEC Filing Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source Source

Annual Balance Sheet

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Cash and Cash Equivalents $2.97B $1.84B $2.94B $2.94B $4.34B
Short Term Investments $82.00M $84.00M $75.00M $81.00M $88.00M
Cash and Short Term Investments $3.05B $1.93B $3.02B $3.02B $4.42B
Net Receivables $3.77B $3.56B $3.02B $2.70B $2.89B
Inventory $4.84B $4.00B $3.31B $3.49B $3.28B
Other Current Assets $857.00M $1.54B $1.18B $960.00M $1.33B
Total Current Assets $12.52B $10.28B $10.02B $9.71B $11.36B
Property Plant Equipment Net $3.21B $2.97B $2.83B $2.75B $2.57B
Goodwill $15.24B $14.88B $12.92B $12.78B $9.07B
Intangible Assets $4.59B $4.88B $4.84B $5.55B $4.23B
Goodwill and Intangible Assets $19.84B $19.77B $17.76B $18.33B $13.30B
Long Term Investments $496.00M $90.00M $66.00M $4.00M $-
Tax Assets $1.67B $1.41B $1.76B $1.53B $1.57B
Other Non-Current Assets $2.67B $2.37B $2.20B $2.00B $1.37B
Total Non-Current Assets $27.39B $26.61B $24.61B $24.62B $18.81B
Other Assets $- $- $- $- $-
Total Assets $39.91B $36.88B $34.63B $34.33B $30.17B
Account Payables $1.52B $1.41B $1.13B $810.00M $675.00M
Short Term Debt $2.24B $1.31B $119.00M $870.00M $945.00M
Tax Payables $391.00M $292.00M $192.00M $207.00M $171.00M
Deferred Revenue $- $- $- $- $-
Other Current Liabilities $3.78B $3.29B $3.11B $3.15B $2.61B
Total Current Liabilities $7.92B $6.30B $4.55B $5.04B $4.40B
Long Term Debt $11.26B $12.21B $12.78B $13.55B $10.53B
Deferred Revenue Non-Current $- $-67.00M $-68.00M $-117.00M $-108.00M
Deferred Tax Liabilities Non-Current $- $67.00M $68.00M $117.00M $108.00M
Other Non-Current Liabilities $2.14B $1.75B $2.42B $2.65B $2.43B
Total Non-Current Liabilities $13.40B $13.96B $15.21B $16.20B $12.96B
Other Liabilities $- $- $- $- $-
Total Liabilities $21.32B $20.27B $19.75B $21.25B $17.36B
Preferred Stock $- $- $- $- $-
Common Stock $38.00M $38.00M $38.00M $38.00M $37.00M
Retained Earnings $16.77B $14.77B $13.48B $12.46B $11.75B
Accumulated Other Comprehensive Income Loss $-416.00M $-221.00M $-531.00M $-1.16B $-606.00M
Other Total Stockholders Equity $2.20B $2.03B $1.89B $1.74B $1.63B
Total Stockholders Equity $18.59B $16.62B $14.88B $13.08B $12.81B
Total Equity $18.59B $16.62B $14.88B $13.08B $12.81B
Total Liabilities and Stockholders Equity $39.91B $36.88B $34.63B $34.33B $30.17B
Minority Interest $- $- $- $- $-
Total Liabilities and Total Equity $39.91B $36.88B $34.63B $34.33B $30.17B
Total Investments $82.00M $84.00M $75.00M $81.00M $88.00M
Total Debt $12.99B $13.05B $12.47B $13.23B $10.23B
Net Debt $10.02B $11.20B $9.53B $10.29B $5.89B


Balance Sheet Charts

Breakdown December 31, 2024 September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020
Cash and Cash Equivalents $3.65B $3.85B $1.87B $2.33B $2.97B $1.86B $1.40B $1.67B $1.84B $1.42B $1.04B $1.46B $2.94B $2.56B $2.24B $2.24B $2.94B $7.08B $6.54B $3.96B
Short Term Investments $750.00M $834.00M $83.00M $77.00M $82.00M $76.00M $77.00M $86.00M $84.00M $77.00M $83.00M $72.00M $75.00M $76.00M $84.00M $74.00M $81.00M $78.00M $80.00M $84.00M
Cash and Short Term Investments $4.40B $4.68B $1.96B $2.41B $3.05B $1.94B $1.48B $1.76B $1.93B $1.50B $1.13B $1.53B $3.02B $2.64B $2.33B $2.31B $3.02B $7.16B $6.62B $4.05B
Net Receivables $3.99B $3.74B $3.62B $3.47B $3.77B $3.28B $3.26B $3.21B $3.56B $3.10B $3.15B $2.99B $3.02B $2.82B $2.71B $2.62B $2.70B $2.43B $2.20B $2.65B
Inventory $4.77B $5.29B $5.04B $5.03B $4.84B $4.88B $4.59B $4.33B $4.00B $3.88B $3.75B $3.52B $3.31B $3.43B $3.43B $3.47B $3.49B $3.46B $3.44B $3.36B
Other Current Assets $1.68B $961.00M $1.02B $986.00M $857.00M $950.00M $819.00M $850.00M $1.54B $1.49B $1.41B $1.26B $1.18B $1.07B $1.07B $1.06B $960.00M $975.00M $1.05B $1.24B
Total Current Assets $14.85B $14.67B $11.64B $11.89B $12.52B $11.04B $10.15B $10.15B $10.28B $9.32B $8.82B $8.72B $10.02B $9.46B $9.03B $8.98B $9.71B $13.54B $12.80B $10.74B
Property Plant Equipment Net $3.45B $3.94B $3.83B $3.26B $3.21B $3.11B $3.08B $3.04B $2.97B $2.80B $2.80B $2.79B $2.83B $2.75B $2.74B $2.71B $2.75B $2.53B $2.53B $2.61B
Goodwill $- $16.40B $15.41B $15.35B $15.24B $15.14B $15.17B $14.85B $14.88B $14.99B $15.12B $15.23B $12.92B $12.89B $12.80B $12.80B $12.78B $9.13B $9.07B $9.03B
Intangible Assets $- $4.94B $4.36B $4.51B $4.59B $4.73B $4.92B $4.78B $4.88B $5.05B $5.25B $5.43B $4.84B $5.06B $5.26B $5.38B $5.55B $3.92B $4.01B $4.11B
Goodwill and Intangible Assets $20.25B $21.34B $19.77B $19.86B $19.84B $19.87B $20.09B $19.63B $19.77B $20.05B $20.36B $20.66B $17.76B $17.95B $18.06B $18.18B $18.33B $13.04B $13.09B $13.13B
Long Term Investments $- $- $16.00M $146.00M $2.00M $12.00M $135.00M $79.00M $90.00M $- $152.00M $75.00M $66.00M $38.00M $23.00M $- $- $- $- $-
Tax Assets $1.74B $1.56B $1.61B $1.64B $1.67B $1.41B $1.44B $1.44B $1.41B $1.39B $1.62B $1.60B $1.76B $1.86B $1.75B $1.52B $1.53B $1.63B $1.57B $1.54B
Other Non-Current Assets $2.68B $2.32B $2.26B $2.60B $2.67B $2.60B $2.51B $2.49B $2.37B $2.43B $2.27B $2.28B $2.20B $2.09B $2.09B $2.07B $2.01B $1.54B $1.50B $1.43B
Total Non-Current Assets $28.12B $29.16B $27.48B $27.51B $27.39B $27.00B $27.26B $26.68B $26.61B $26.66B $27.21B $27.41B $24.61B $24.68B $24.67B $24.48B $24.62B $18.74B $18.68B $18.70B
Other Assets $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Assets $42.97B $43.83B $39.13B $39.40B $39.91B $38.04B $37.41B $36.83B $36.88B $35.98B $36.03B $36.14B $34.63B $34.15B $33.70B $33.45B $34.33B $32.29B $31.48B $29.44B
Account Payables $- $1.34B $1.30B $1.25B $1.52B $1.30B $1.33B $1.37B $1.41B $1.21B $1.16B $1.08B $1.13B $934.00M $864.00M $767.00M $810.00M $647.00M $635.00M $736.00M
Short Term Debt $12.19B $2.16B $2.24B $2.21B $2.24B $2.44B $1.92B $1.34B $1.31B $124.00M $125.00M $343.00M $119.00M $130.00M $115.00M $124.00M $870.00M $1.22B $1.20B $1.19B
Tax Payables $349.00M $394.00M $334.00M $444.00M $391.00M $465.00M $469.00M $371.00M $292.00M $243.00M $300.00M $173.00M $192.00M $373.00M $300.00M $253.00M $207.00M $261.00M $214.00M $227.00M
Deferred Revenue $- $- $-11.43B $-1.25B $7.32B $-1.30B $-1.33B $- $1.41B $1.39B $1.62B $- $- $373.00M $300.00M $253.00M $207.00M $261.00M $214.00M $227.00M
Other Current Liabilities $-4.92B $3.78B $3.05B $3.05B $3.78B $3.26B $2.87B $2.79B $3.29B $2.99B $2.82B $2.81B $3.11B $3.01B $2.97B $2.81B $3.15B $2.56B $2.35B $2.01B
Total Current Liabilities $7.62B $7.67B $6.93B $6.96B $7.92B $7.46B $6.58B $5.87B $6.30B $4.57B $4.40B $4.41B $4.55B $4.45B $4.25B $3.95B $5.04B $4.69B $4.41B $4.16B
Long Term Debt $- $13.32B $10.51B $11.19B $11.26B $10.75B $11.51B $12.22B $12.21B $13.10B $13.73B $14.26B $12.78B $12.93B $13.04B $13.38B $13.55B $12.32B $12.13B $9.71B
Deferred Revenue Non-Current $- $- $- $- $-63.00M $- $- $- $-67.00M $- $- $- $-847.00M $-931.00M $- $- $- $- $- $-
Deferred Tax Liabilities Non-Current $- $- $- $- $63.00M $- $- $- $67.00M $1.39B $1.62B $1.60B $1.76B $1.86B $- $- $- $- $- $-
Other Non-Current Liabilities $- $2.69B $1.94B $2.09B $2.14B $1.93B $1.95B $1.84B $1.75B $1.85B $2.23B $2.43B $2.42B $2.59B $2.59B $2.62B $2.65B $2.29B $2.19B $2.45B
Total Non-Current Liabilities $- $16.02B $12.44B $13.28B $13.40B $12.68B $13.46B $14.07B $13.96B $14.95B $15.95B $16.68B $15.21B $15.52B $15.63B $16.00B $16.20B $14.61B $14.32B $12.16B
Other Liabilities $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities $- $23.68B $19.37B $20.23B $21.32B $20.14B $20.05B $19.93B $20.27B $19.52B $20.36B $21.09B $19.75B $19.97B $19.88B $19.95B $21.25B $19.30B $18.73B $16.32B
Preferred Stock $- $- $- $19.13B $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Common Stock $- $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M $38.00M
Retained Earnings $- $18.30B $17.77B $17.25B $16.77B $15.93B $15.53B $15.07B $14.77B $14.49B $13.93B $13.54B $13.48B $13.08B $12.88B $12.53B $12.46B $12.13B $11.72B $12.02B
Accumulated Other Comprehensive Income Loss $- $-545.00M $-355.00M $-377.00M $-416.00M $-249.00M $-330.00M $-305.00M $-221.00M $-89.00M $-286.00M $-479.00M $-531.00M $-816.00M $-943.00M $-867.00M $-1.16B $-917.00M $-715.00M $-623.00M
Other Total Stockholders Equity $42.97B $2.35B $2.31B $2.26B $2.20B $2.18B $2.13B $2.09B $2.03B $2.03B $1.99B $1.95B $1.89B $1.88B $1.84B $1.81B $1.74B $1.74B $1.71B $1.68B
Total Stockholders Equity $42.97B $20.15B $19.76B $19.17B $18.59B $17.91B $17.36B $16.89B $16.62B $16.46B $15.67B $15.05B $14.88B $14.18B $13.82B $13.50B $13.08B $12.99B $12.75B $13.12B
Total Equity $42.97B $20.15B $19.76B $19.17B $18.59B $17.91B $17.36B $16.89B $16.62B $16.46B $15.67B $15.05B $14.88B $14.18B $13.82B $13.50B $13.08B $12.99B $12.75B $13.12B
Total Liabilities and Stockholders Equity $42.97B $43.83B $39.13B $39.40B $39.91B $38.04B $37.41B $36.83B $36.88B $35.98B $36.03B $36.14B $34.63B $34.15B $33.70B $33.45B $34.33B $32.29B $31.48B $29.44B
Minority Interest $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $- $-
Total Liabilities and Total Equity $42.97B $43.83B $39.13B $39.40B $39.91B $38.04B $37.41B $36.83B $36.88B $35.98B $36.03B $36.14B $34.63B $34.15B $33.70B $33.45B $34.33B $32.29B $31.48B $29.44B
Total Investments $750.00M $834.00M $99.00M $77.00M $82.00M $76.00M $77.00M $86.00M $84.00M $77.00M $83.00M $72.00M $75.00M $76.00M $84.00M $74.00M $81.00M $78.00M $80.00M $84.00M
Total Debt $12.19B $15.48B $12.74B $10.81B $12.99B $10.38B $11.15B $11.86B $13.05B $12.75B $13.37B $14.10B $12.47B $12.63B $12.73B $13.06B $13.23B $12.01B $11.81B $9.40B
Net Debt $8.54B $11.63B $10.87B $8.48B $10.02B $8.52B $9.75B $10.19B $11.20B $11.33B $12.33B $12.64B $9.53B $10.07B $10.49B $10.82B $10.29B $4.92B $5.27B $5.44B

Annual Cash Flow

Breakdown December 31, 2023 December 31, 2022 December 31, 2021 December 31, 2020 December 31, 2019
Net Income $3.17B $2.36B $1.99B $1.60B $2.08B
Depreciation and Amortization $1.03B $998.00M $990.00M $812.00M $778.00M
Deferred Income Tax $-206.00M $58.00M $-237.00M $48.00M $126.00M
Stock Based Compensation $205.00M $168.00M $171.00M $142.00M $127.00M
Change in Working Capital $-500.00M $-732.00M $279.00M $866.00M $-670.00M
Accounts Receivables $-175.00M $-579.00M $-377.00M $354.00M $-563.00M
Inventory $-797.00M $-762.00M $-189.00M $27.00M $-400.00M
Accounts Payables $77.00M $290.00M $329.00M $100.00M $63.00M
Other Working Capital $395.00M $319.00M $516.00M $385.00M $230.00M
Other Non Cash Items $19.00M $-226.00M $66.00M $-190.00M $-253.00M
Net Cash Provided by Operating Activities $3.71B $2.62B $3.26B $3.28B $2.19B
Investments in Property Plant and Equipment $-575.00M $-588.00M $-525.00M $-487.00M $-649.00M
Acquisitions Net $-390.00M $-2.56B $-339.00M $-4.22B $-802.00M
Purchases of Investments $-52.00M $-52.00M $-49.00M $-54.00M $-74.00M
Sales Maturities of Investments $54.00M $240.00M $55.00M $61.00M $69.00M
Other Investing Activities $1.00M $39.00M $-1.00M $1.00M $1.00M
Net Cash Used for Investing Activities $-962.00M $-2.92B $-859.00M $-4.70B $-1.46B
Debt Repayment $-277.00M $472.00M $-1.15B $989.00M $1.29B
Common Stock Issued $- $- $114.00M $- $-
Common Stock Repurchased $-155.00M $-122.00M $-114.00M $-110.00M $-307.00M
Dividends Paid $-1.14B $-1.05B $-950.00M $-863.00M $-778.00M
Other Financing Activities $-178.00M $-170.00M $-269.00M $-27.00M $-205.00M
Net Cash Used Provided by Financing Activities $-1.59B $-749.00M $-2.37B $-11.00M $3.00M
Effect of Forex Changes on Cash $-28.00M $-51.00M $-38.00M $41.00M $-18.00M
Net Change in Cash $1.13B $-1.10B $1.00M $-1.39B $721.00M
Cash at End of Period $2.97B $1.84B $2.94B $2.94B $4.34B
Cash at Beginning of Period $1.84B $2.94B $2.94B $4.34B $3.62B
Operating Cash Flow $3.71B $2.62B $3.26B $3.28B $2.19B
Capital Expenditure $-575.00M $-588.00M $-525.00M $-487.00M $-649.00M
Free Cash Flow $3.14B $2.04B $2.74B $2.79B $1.54B

Cash Flow Charts

Breakdown September 30, 2024 June 30, 2024 March 31, 2024 December 31, 2023 September 30, 2023 June 30, 2023 March 31, 2023 December 31, 2022 September 30, 2022 June 30, 2022 March 31, 2022 December 31, 2021 September 30, 2021 June 30, 2021 March 31, 2021 December 31, 2020 September 30, 2020 June 30, 2020 March 31, 2020 December 31, 2019
Net Income $834.00M $825.00M $788.00M $1.14B $692.00M $738.00M $592.00M $563.00M $816.00M $656.00M $323.00M $662.00M $438.00M $592.00M $302.00M $568.00M $621.00M $-83.00M $493.00M $725.00M
Depreciation and Amortization $268.00M $258.00M $260.00M $250.00M $262.00M $259.00M $257.00M $253.00M $250.00M $253.00M $242.00M $238.00M $235.00M $241.00M $276.00M $223.00M $198.00M $193.00M $198.00M $195.00M
Deferred Income Tax $10.00M $8.00M $-39.00M $-182.00M $- $- $-3.00M $58.00M $- $- $- $-29.00M $-127.00M $-18.00M $-145.00M $-83.00M $-30.00M $-25.00M $-52.00M $-52.00M
Stock Based Compensation $51.00M $46.00M $87.00M $40.00M $52.00M $39.00M $74.00M $28.00M $33.00M $36.00M $71.00M $30.00M $34.00M $39.00M $68.00M $27.00M $29.00M $30.00M $56.00M $32.00M
Change in Working Capital $280.00M $-529.00M $-844.00M $278.00M $192.00M $-247.00M $-404.00M $187.00M $-177.00M $-380.00M $-362.00M $100.00M $260.00M $45.00M $-126.00M $446.00M $10.00M $510.00M $-100.00M $-185.00M
Accounts Receivables $-36.00M $-155.00M $258.00M $-441.00M $-42.00M $-57.00M $365.00M $-393.00M $-27.00M $-212.00M $53.00M $-232.00M $-121.00M $-89.00M $65.00M $-113.00M $-204.00M $467.00M $204.00M $-439.00M
Inventory $-132.00M $-46.00M $-184.00M $125.00M $-333.00M $-275.00M $-314.00M $-8.00M $-231.00M $-294.00M $-229.00M $42.00M $-103.00M $-55.00M $-73.00M $181.00M $27.00M $-59.00M $-122.00M $14.00M
Accounts Payables $2.00M $52.00M $-257.00M $195.00M $-21.00M $-41.00M $-56.00M $179.00M $77.00M $86.00M $-52.00M $195.00M $77.00M $94.00M $-37.00M $126.00M $8.00M $-97.00M $63.00M $26.00M
Other Working Capital $446.00M $-380.00M $-844.00M $399.00M $588.00M $126.00M $-399.00M $409.00M $4.00M $40.00M $-134.00M $95.00M $407.00M $95.00M $-81.00M $252.00M $179.00M $199.00M $-245.00M $214.00M
Other Non Cash Items $31.00M $736.00M $520.00M $-1.00M $-96.10M $-62.20M $-74.00M $-86.00M $-33.00M $-36.00M $-71.00M $-1.00M $93.00M $-21.00M $77.00M $56.00M $1.00M $-5.00M $-4.00M $20.00M
Net Cash Provided by Operating Activities $1.47B $633.00M $204.00M $1.53B $1.05B $688.00M $445.00M $1.00B $889.00M $529.00M $203.00M $1.00B $933.00M $878.00M $452.00M $1.24B $829.00M $620.00M $591.00M $735.00M
Investments in Property Plant and Equipment $-170.00M $-152.00M $-167.00M $-145.00M $-148.00M $-152.00M $-130.00M $-188.00M $-138.00M $-143.00M $-119.00M $-206.00M $-130.00M $-106.00M $-83.00M $-165.00M $-69.00M $-109.00M $-144.00M $-199.00M
Acquisitions Net $-1.26B $-88.00M $-246.00M $-246.00M $-1.00M $-390.00M $- $- $- $- $-2.56B $-113.00M $-122.00M $-77.00M $-27.00M $-4.20B $- $-3.00M $-23.00M $-521.00M
Purchases of Investments $-759.00M $-14.00M $-18.00M $-11.00M $-6.00M $-7.00M $-28.00M $-9.00M $-5.00M $-29.00M $-9.00M $-11.00M $-7.00M $-26.00M $-5.00M $-20.00M $-11.00M $-15.00M $-8.00M $-17.00M
Sales Maturities of Investments $9.00M $107.00M $23.00M $5.00M $7.00M $17.00M $25.00M $3.00M $208.00M $18.00M $11.00M $12.00M $15.00M $16.00M $12.00M $17.00M $13.00M $19.00M $12.00M $17.00M
Other Investing Activities $12.00M $30.00M $5.00M $-1.00M $3.00M $-1.00M $1.00M $32.00M $7.00M $2.00M $-2.00M $4.00M $-3.00M $-9.00M $7.00M $12.00M $-2.00M $-9.00M $4.00M $1.00M
Net Cash Used for Investing Activities $-2.17B $-117.00M $-408.00M $-152.00M $-145.00M $-533.00M $-132.00M $-162.00M $72.00M $-152.00M $-2.68B $-314.00M $-247.00M $-202.00M $-96.00M $-4.35B $-69.00M $-117.00M $-163.00M $-719.00M
Debt Repayment $2.98B $-599.00M $-1.00M $35.00M $-107.00M $-103.00M $-102.00M $-150.00M $-250.00M $-458.00M $1.33B $- $14.00M $-410.00M $-743.00M $-807.00M $-5.00M $2.30B $-496.00M $2.64B
Common Stock Issued $- $- $- $- $- $-2.00M $- $33.00M $5.00M $- $- $- $- $- $- $- $- $- $- $-
Common Stock Repurchased $- $-14.00M $-113.00M $-34.00M $-10.00M $-17.00M $-94.00M $-33.00M $-5.00M $-12.00M $-72.00M $-26.00M $-14.00M $-21.00M $-53.00M $-31.00M $-11.00M $-12.00M $-56.00M $-6.00M
Dividends Paid $-305.00M $-305.00M $-304.00M $-285.00M $-285.00M $-285.00M $-284.00M $-263.00M $-263.00M $-263.00M $-262.00M $-237.00M $-238.00M $-237.00M $-238.00M $-216.00M $-216.00M $-216.00M $-215.00M $-193.00M
Other Financing Activities $-20.00M $-62.00M $-113.00M $-36.00M $-30.00M $-17.00M $-95.00M $-33.00M $-30.00M $-32.00M $-75.00M $-51.00M $-124.00M $-29.00M $-72.00M $-3.00M $-21.00M $-25.00M $-57.00M $-85.00M
Net Cash Used Provided by Financing Activities $2.65B $-966.00M $-418.00M $-286.00M $-422.00M $-405.00M $-481.00M $-446.00M $-543.00M $-753.00M $993.00M $-288.00M $-348.00M $-676.00M $-1.05B $-1.06B $-242.00M $2.06B $-768.00M $2.36B
Effect of Forex Changes on Cash $21.00M $-6.00M $-19.00M $21.00M $-24.00M $-20.00M $-5.00M $29.00M $-42.00M $-38.00M $- $-17.00M $-16.00M $3.00M $-8.00M $32.00M $26.00M $16.00M $-33.00M $10.00M
Net Change in Cash $1.98B $-456.00M $-641.00M $1.11B $-942.00M $-1.94B $-2.02B $424.00M $376.00M $-414.00M $-1.49B $381.00M $322.00M $3.00M $-705.00M $-4.14B $544.00M $2.58B $-373.00M $2.69B
Cash at End of Period $3.85B $1.87B $2.33B $2.97B $459.00M $-270.00M $-173.00M $1.84B $1.42B $1.04B $1.46B $2.94B $2.56B $2.24B $2.24B $2.94B $7.08B $6.54B $3.96B $4.34B
Cash at Beginning of Period $1.87B $2.33B $2.97B $1.86B $1.40B $1.67B $1.84B $1.42B $1.04B $1.46B $2.94B $2.56B $2.24B $2.24B $2.94B $7.08B $6.54B $3.96B $4.34B $1.65B
Operating Cash Flow $1.47B $633.00M $204.00M $1.53B $1.05B $688.00M $445.00M $1.00B $889.00M $529.00M $203.00M $1.00B $933.00M $878.00M $452.00M $1.24B $829.00M $620.00M $591.00M $735.00M
Capital Expenditure $-170.00M $-152.00M $-167.00M $-145.00M $-148.00M $-152.00M $-130.00M $-188.00M $-138.00M $-143.00M $-119.00M $-206.00M $-130.00M $-106.00M $-83.00M $-165.00M $-69.00M $-109.00M $-144.00M $-199.00M
Free Cash Flow $1.30B $481.00M $37.00M $1.38B $902.00M $536.00M $315.00M $815.00M $751.00M $386.00M $84.00M $794.00M $803.00M $772.00M $369.00M $1.07B $760.00M $511.00M $447.00M $536.00M


Stryker Stock Forecast

Analyst ratings, price targets, and earnings estimates for SYK.

SYK Analyst Ratings

Strong Buy

Buy
15
Hold
4
Sell
0

Based on 19 analysts in the past 3 months

SYK Stock 12 Month Forecast

$434.67

▲ (9.99% Upside)
Highest Price Target
$ (0.0%)
Average Price Target
$434.67 (10.0%)
Lowest Price Target
$ (0.0%)

Based on 3 analysts in the last 3 months

Recent Price Targets
Recommendation Trends
Analyst Estimates
Revenue Estimates
High $24.81B
Average $24.48B
Low $24.11B
19 analysts
Net Income Estimates
High $5.26B
Average $5.17B
Low $5.08B
19 analysts
EPS Estimates
High $13.70
Average $13.49
Low $13.25
16 analysts
Revenue Estimates
High $26.76B
Average $26.35B
Low $25.36B
20 analysts
Net Income Estimates
High $5.91B
Average $5.62B
Low $5.33B
20 analysts
EPS Estimates
High $15.40
Average $14.89
Low $13.90
16 analysts
Revenue Estimates
High $28.67B
Average $28.58B
Low $28.48B
12 analysts
Net Income Estimates
High $6.95B
Average $6.39B
Low $5.82B
12 analysts
EPS Estimates
High $18.12
Average $16.61
Low $15.17
4 analysts
Revenue Estimates
High $31.51B
Average $31.09B
Low $30.28B
5 analysts
Net Income Estimates
High $7.17B
Average $7.05B
Low $6.81B
5 analysts
EPS Estimates
High $18.69
Average $18.36
Low $17.74
2 analysts
Revenue Estimates
High $33.88B
Average $33.43B
Low $32.56B
10 analysts
Net Income Estimates
High $8.05B
Average $7.91B
Low $7.64B
10 analysts
EPS Estimates
High $20.97
Average $20.61
Low $19.92
1 analysts
Latest Price Target Updates
Date Analyst Firm Price Target Price When Posted Upside
Feb 03, 2025 David Toung Argus Research $450.00 $391.14 15.0%
Dec 18, 2024 Richard Newitter Truist Financial $409.00 $359.17 13.9%
Dec 02, 2024 Patrick Wood Morgan Stanley $445.00 $390.90 13.8%
Oct 31, 2024 Joanne Wuensch Citigroup $411.00 $363.43 13.1%
Oct 30, 2024 Matt O'Brien Piper Sandler $420.00 $367.95 14.1%
Oct 30, 2024 Richard Newitter Truist Financial $380.00 $365.42 4.0%
Oct 30, 2024 Kyle Rose Canaccord Genuity $400.00 $359.01 11.4%
Oct 30, 2024 Ryan Zimmerman BTIG $394.00 $359.01 9.7%
Oct 14, 2024 Richard Newitter Truist Financial $370.00 $356.45 3.8%
Sep 10, 2024 Matt O\'Brien Piper Sandler $380.00 $365.22 4.0%

Stryker Dividends

Explore Stryker's dividend history, including dividend yield, payout ratio, and historical payments.

Dividend Yield

1.00%

Dividend Payout Ratio

35.99%

Dividend Paid & Capex Coverage Ratio

2.17x



Stryker Dividend History

Dividend Adjusted Dividend Date Record Date Payment Date Declaration Date
$0.84 $0.84 March 31, 2025 March 31, 2025 April 30, 2025 February 05, 2025
$0.84 $0.84 December 31, 2024 December 31, 2024 January 31, 2025 December 10, 2024
$0.8 $0.8 September 30, 2024 September 30, 2024 October 31, 2024 August 07, 2024
$0.8 $0.8 June 28, 2024 June 28, 2024 July 31, 2024 May 09, 2024
$0.8 $0.8 March 27, 2024 March 29, 2024 April 30, 2024 February 07, 2024
$0.8 $0.8 December 28, 2023 December 29, 2023 January 31, 2024 December 05, 2023
$0.75 $0.75 September 28, 2023 September 29, 2023 October 31, 2023 August 02, 2023
$0.75 $0.75 June 29, 2023 June 30, 2023 July 31, 2023 May 10, 2023
$0.75 $0.75 March 30, 2023 March 31, 2023 April 28, 2023 February 09, 2023
$0.75 $0.75 December 29, 2022 December 30, 2022 January 31, 2023 December 07, 2022
$0.695 $0.695 September 29, 2022 September 30, 2022 October 31, 2022 August 03, 2022
$0.695 $0.695 June 29, 2022 June 30, 2022 July 29, 2022 May 04, 2022
$0.695 $0.695 March 30, 2022 March 31, 2022 April 29, 2022 February 02, 2022
$0.695 $0.695 December 30, 2021 December 31, 2021 January 31, 2022 December 09, 2021
$0.63 $0.63 September 29, 2021 September 30, 2021 October 29, 2021 August 04, 2021
$0.63 $0.63 June 29, 2021 June 30, 2021 July 30, 2021 May 04, 2021
$0.63 $0.63 March 30, 2021 March 31, 2021 April 30, 2021 February 02, 2021
$0.63 $0.63 December 30, 2020 December 31, 2020 January 29, 2021 December 02, 2020
$0.575 $0.575 September 29, 2020 September 30, 2020 October 30, 2020 July 30, 2020
$0.575 $0.575 June 29, 2020 June 30, 2020 July 31, 2020 May 05, 2020

Peers: Medical - Devices

This section provides companies within the same sector, on the same exchange, and of similar market capitalization, allowing comparisons of key financial indicators among peers.

Company Market Cap Price EPS P/E Ratio P/B Ratio
BSX Logo
Boston Scientific Corporation
BSX
$152.94B $103.77 $1.10 $52.73 $4.36
ABT Logo
Abbott Laboratories
ABT
$222.39B $128.22 $3.30 $33.35 $4.94
MDT Logo
Medtronic plc
MDT
$116.19B $90.61 $2.77 $28.80 $2.11
DXCM Logo
DexCom, Inc.
DXCM
$34.68B $88.80 $1.40 $88.46 $23.16
EW Logo
Edwards Lifesciences Corporation
EW
$41.87B $70.99 $2.31 $32.99 $6.96
 Logo
$- $ $ $ $
ZBH Logo
Zimmer Biomet Holdings, Inc.
ZBH
$20.63B $103.65 $0.00 $0.00 $0.00
ZIMV Logo
ZimVie Inc.
ZIMV
$382.80M $13.87 $-14.87 $-1.19 $1.15
STE Logo
STERIS plc
STE
$22.25B $225.44 $3.83 $57.73 $3.46
SNN Logo
Smith & Nephew plc
SNN
$10.93B $25.08 $0.30 $45.15 $2.28
Ownership